Erythropoiesis-stimulating agents (ESA) for preventing the progression of chronic kidney disease: a meta-analysis of 19 studies.

@article{Covic2014ErythropoiesisstimulatingA,
  title={Erythropoiesis-stimulating agents (ESA) for preventing the progression of chronic kidney disease: a meta-analysis of 19 studies.},
  author={Adrian Constantin Covic and Ionuţ Nistor and Mihaela-Dora Donciu and Raluca Dumea and Davide Bolignano and David Goldsmith},
  journal={American journal of nephrology},
  year={2014},
  volume={40 3},
  pages={263-79}
}
BACKGROUND The effect of anemia correction on kidney function in chronic kidney disease (CKD) patients remains unclear. As 19-40% of patients with CKD receive an erythropoiesis-stimulating agent (ESA), this is a potentially important consideration. SUMMARY We conducted a systematic review and meta-analysis of randomized trials to January 1, 2014 in adult patients with CKD stages 1 to 4. SELECTION CRITERIA FOR STUDIES randomized controlled trials of at least 2 months duration. Patients were… CONTINUE READING